drugset / Trial / NCT05042310

A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants

NCT05042310 ↗

Phase 1 Completed 94 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3541860 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3541860 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 113 days.

Timeline

Start
2021-11-11
Primary completion
2023-12-27
Completion
2023-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3541860 Unknown — Intravenous

Indications

No indication recorded.